For this reason, HER2 testing is recommended for all newly diagnosed breast cancer patients for the selection of individuals that may benefit from treatment with the humanized monoclonal antibody Trastuzumab [8–11]. The gene discussed is ERBB2; the disease is breast carcinoma.